Original Text: |
    Concurrently using other anticancer therapy. Participants must continue palbociclib and AI or fulvestrant for Phase 1b and palbociclib or ribociclib and AI or fulvestrant for Phase 2.
Disease/Condition: none
Procedure: none
Drug: none
Biomarker: none
Computable Rule: |
    "Concurrently using other anticancer therapy" is False
